Bing Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bing Yuan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Danni Ai
Beijing Institute of Technology
1 shared publication - Ding-Kun Liu
Beijing Institute of Technology
1 shared publication - Feng Duan
Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China
1 shared publication - Jian Yang
Beijing Institute of Technology
1 shared publication - Jiangtao Liu
Faculty of Liver Disease of Chinese PLA General Hospital, The Fifth Medical of Chinese PLA General Hospital, Beijing, China
1 shared publication - Jie-Yu Yan
Department of Interventional Radiology, the General Hospital of Chinese People’s Liberation Army, Beijing, 100853, China
1 shared publication
Latest Publications
- Open Access
- 4 December 2024
- Published by Springer Nature in Research Square
Evaluation of response to Targeted therapy and immunotherapy for advanced HCCs: A retrospective, controlled study
Background: To validate the correlation between radiomics extracted from magnetic resonance imaging (MRI) and pathologic alterations in advanced hepatocellular carcinoma (HCC) treated with targeted therapy and immunotherapy, and to compare the accuracy of necrosis evaluation by radiologists and subtraction technology. Methods: Thirty-five patients diagnosed unresectable HCCs (n = 39) who underwent curative resection at two centers after receiving combined treatment with tyrosine kinase inhibitors and programmed death ligand-1 antibodies were included. Using linear regression model to verify the consistency between investigator-based imaging evaluation and three-dimensional (3D) subtraction-based imaging analysis and their capability to distinguish major pathological response (MPR) and pathological complete remission (PCR) were compared using receiver operating characteristic (ROC) curve analysis with pathological outcome as the gold standard.The sensitivity, specificity, and area under the ROC curve (AUC) were compared. Results: 3D subtraction-based imaging analysis suggested a strong correlation with histopathologic alteration (R2 = 0.81) and was superior in classifying MPR or PCR comparing to the use of investigator-based imaging evaluation (area under the receiver operator characteristic curve: MRP, 0.80 vs. 0.52; PCR, 0.69 vs. 0.54). Conclusion: 3D subtraction-based imaging analysis based on tumor characteristics showed a stronger correlation with pathology, and 3D subtraction-based imaging analysis was significantly superior to investigator-based imaging evaluation in classifying MPR or PCR.
- 4 December 2024
- Published by Springer Nature in Research Square
Open AccessEvaluation of response to Targeted therapy and immunotherapy for advanced HCCs: A retrospective, controlled study
Background: To validate the correlation between radiomics extracted from magnetic resonance imaging (MRI) and pathologic alterations in advanced hepatocellular carcinoma (HCC) treated with targeted therapy and immunotherapy, and to compare the accuracy of necrosis evaluation by radiologists and subtraction technology. Methods: Thirty-five patients diagnosed unresectable HCCs (n = 39) who underwent curative resection at two centers after receiving combined treatment with tyrosine kinase inhibitors and programmed death ligand-1 antibodies were included. Using linear regression model to verify the consistency between investigator-based imaging evaluation and three-dimensional (3D) subtraction-based imaging analysis and their capability to distinguish major pathological response (MPR) and pathological complete remission (PCR) were compared using receiver operating characteristic (ROC) curve analysis with pathological outcome as the gold standard.The sensitivity, specificity, and area under the ROC curve (AUC) were compared. Results: 3D subtraction-based imaging analysis suggested a strong correlation with histopathologic alteration (R2 = 0.81) and was superior in classifying MPR or PCR comparing to the use of investigator-based imaging evaluation (area under the receiver operator characteristic curve: MRP, 0.80 vs. 0.52; PCR, 0.69 vs. 0.54). Conclusion: 3D subtraction-based imaging analysis based on tumor characteristics showed a stronger correlation with pathology, and 3D subtraction-based imaging analysis was significantly superior to investigator-based imaging evaluation in classifying MPR or PCR.
- Open Access
- 9 July 2020
- Published by KEAI Publishing in Journal of Interventional Medicine
- Vol. 3 (3) , 142-145
Prostate artery embolization for the treatment of urinary retention caused by large (>80 mL) benign prostatic hyperplasia: Results of 21 patients
A large prostate size (>80 mL) of benign prostatic hyperplasia (BPH) is technically challenging to treat surgically. This study aimed to investigate the safety and efficacy of super-selective prostatic artery embolization (PAE) for the treatment of urinary retention caused by large BPH. A total of 21 patients with urinary retention, indwelling urinary catheter, or suprapubic cystostomy as a consequence of giant BPH (prostate volume [PV] > 80 mL) who sought treatment between January 2013 and December 2017 were enrolled. A microcatheter (1.9–2.7 Fr) and a “two-step embolization” combining 50-μm and 100-μm polyvinyl alcohol embolization particles were used in all patients. International Prostate Symptom Score (IPSS), quality of life (QoL), PV, and prostate-specific antigen (PSA) were evaluated at 3, 6, and 12 months post-PAE. Clinical success was defined as removal of urinary catheter or suprapubic cystostomy and ability to void spontaneously. The clinical success rate was 95.2% (20/21). Compared with pre-procedural values, IPSS, QoL, PV, and PSA showed statistically significant differences at 3, 6, and 12 months post-PAE (P < 0.05). There were no serious complications after PAE. PAE was safe and effective for the treatment of urinary retention caused by large BPH in patients without surgical treatment options.
- 9 July 2020
- Published by KEAI Publishing in Journal of Interventional Medicine
- Vol. 3 (3) , 142-145
Open AccessProstate artery embolization for the treatment of urinary retention caused by large (>80 mL) benign prostatic hyperplasia: Results of 21 patients
A large prostate size (>80 mL) of benign prostatic hyperplasia (BPH) is technically challenging to treat surgically. This study aimed to investigate the safety and efficacy of super-selective prostatic artery embolization (PAE) for the treatment of urinary retention caused by large BPH. A total of 21 patients with urinary retention, indwelling urinary catheter, or suprapubic cystostomy as a consequence of giant BPH (prostate volume [PV] > 80 mL) who sought treatment between January 2013 and December 2017 were enrolled. A microcatheter (1.9–2.7 Fr) and a “two-step embolization” combining 50-μm and 100-μm polyvinyl alcohol embolization particles were used in all patients. International Prostate Symptom Score (IPSS), quality of life (QoL), PV, and prostate-specific antigen (PSA) were evaluated at 3, 6, and 12 months post-PAE. Clinical success was defined as removal of urinary catheter or suprapubic cystostomy and ability to void spontaneously. The clinical success rate was 95.2% (20/21). Compared with pre-procedural values, IPSS, QoL, PV, and PSA showed statistically significant differences at 3, 6, and 12 months post-PAE (P < 0.05). There were no serious complications after PAE. PAE was safe and effective for the treatment of urinary retention caused by large BPH in patients without surgical treatment options.